MedTrace Logo

Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

NCT03652974 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2022-09-06

No results posted yet for this study

Summary

In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).

Conditions

Interventions

DRUG

sodium valproate with Clozapine

sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

DEVICE

modified electroconvulsive therapy(MECT) with Clozapine

modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

DRUG

amisulpride with Clozapine

amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

DRUG

placebo with Clozapine

placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

Sponsors & Collaborators

  • Shanghai Pudong New Area Mental Health Center

    collaborator UNKNOWN

  • The Affiliated Brain Hospital of Guangzhou Medical University

    collaborator UNKNOWN

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Zezhi Li, M.D. · Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-06
Primary Completion
2021-08-30
Completion
2021-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652974 on ClinicalTrials.gov